[Non-resorbable antibiotic improves prognosis in liver cirrhosis].
H S
HS
Füessl
D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D019072:Antibiotic Prophylaxis; D001419:Bacteria / Q000187:drug effects*; D018849:Controlled Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D006975:Hypertension, Portal / Q000097:blood* / Q000517:prevention & control*; D007408:Intestinal Absorption / Q000502:physiology; D007422:Intestines / Q000382:microbiology*; D008104:Liver Cirrhosis, Alcoholic / Q000097:blood* / Q000188:drug therapy* / Q000401:mortality; D008134:Long-Term Care; D010538:Peritonitis / Q000097:blood / Q000382:microbiology / Q000517:prevention & control; D012294:Rifamycins / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D000078262:Rifaximin; D015996:Survival Rate
D000890:Anti-Infective Agents; D012294:Rifamycins; D000078262:Rifaximin